论文部分内容阅读
目的:探讨为接受骨科手术的患者用低分子肝素预防其发生下肢深静脉血栓的临床效果。方法:选取近年来在我院接受骨科手术的98例患者作为研究对象。随机将这些患者分为对照组(44例)和观察组(54例)。在手术结束后,对对照组患者不采取任何预防其发生下肢深静脉血栓的措施,仅对其患肢皮肤的温度、颜色、水肿程度等进行观察。为观察组患者使用低分子肝素预防其发生下肢深静脉血栓。然后,比较两组患者发生术后并发症的情况、其血小板计数及凝血功能的各项指标。结果:观察组患者术后并发症的总发生率明显低于对照组患者,且其下肢深静脉血栓的发生率明显低于对照组患者,组间比较差异具有统计学意义(P<0.05)。两组患者的血小板计数、凝血功能的各项指标相比较,差异无统计学意义(P>0.05)。结论:对接受骨科手术的患者用低分子肝素预防其发生下肢深静脉血栓的效果显著。此药可作为接受骨科手术的患者预防其发生下肢深静脉血栓的优选药物。
Objective: To investigate the clinical effect of low molecular weight heparin for prevention of deep venous thrombosis of lower extremities in patients undergoing orthopedic surgery. Methods: Select 98 cases of orthopedic surgery in our hospital in recent years as the research object. These patients were randomly divided into control group (44 cases) and observation group (54 cases). At the end of the operation, the control group did not take any measures to prevent the occurrence of deep venous thrombosis of the lower extremities. Only the temperature, color and edema of the affected limbs were observed. For the observation group patients with low molecular weight heparin to prevent the occurrence of deep venous thrombosis. Then, comparisons of postoperative complications between the two groups of patients, their platelet count and coagulation parameters were compared. Results: The total incidence of postoperative complications in the observation group was significantly lower than that in the control group, and the incidence of deep venous thrombosis in lower limbs was significantly lower than that in the control group. There was significant difference between the two groups (P <0.05). The two groups of patients with platelet count, coagulation function of the various indicators compared, the difference was not statistically significant (P> 0.05). Conclusion: The effect of low molecular weight heparin on the prevention of deep venous thrombosis in lower extremity was significant in patients undergoing orthopedic surgery. This medicine can be used as orthopedic surgery in patients with the prevention of its occurrence of deep vein thrombosis of the preferred drug.